CSL-VIFOR
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each (each a "Vifor Share"). The Commercial Court's decision has become legally effective (rechtskräftig) and is published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt; SHAB) by the Commercial Court.
Vifor further announced today that SIX Exchange Regulation AG has determined the last trading day and the delisting date of the Vifor Shares at and from SIX Swiss Exchange as follows:
Last trading day: 22 December 2022
Delisting date: 23 December 2022
As a result of the cancellation of the remaining publicly held Vifor Shares, each holder of cancelled Vifor Shares is entitled to a compensation of USD 179.25 in cash per cancelled Vifor Share. The envisaged settlement date for payment of such compensation against delivery of the cancelled Vifor Shares is 28 December 2022.
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
Forward-Looking Statements
This announcement may contain statements that constitute forward-looking statements. The words “anticipate”, “believe”, “expect”, "estimate", "aim", “project”, “forecast”, “estimate”, "risk", “likely”, “intend”, “outlook”, “should”, “could”, "would", “may”, "will", "continue", "plan", "probability", "indicative", "seek", “target”, “plan” and other similar expressions are intended to identify forward-looking statements.
Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of CSL and Vifor and their officers, employees, agents and advisors, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and may cause actual results to differ materially from those expressed or implied in such statements. You are strongly cautioned not to place undue reliance on forward-looking statements.
This announcement is not a financial product or investment advice, a recommendation to acquire or sell securities or accounting, legal or tax advice. It does not constitute an invitation or offer to apply for securities. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate for their jurisdiction. CSL and Vifor are not licensed to provide financial product advice in respect of an investment in securities.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005876/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DENTALIS-ANIMAL-HEALTH4.2.2023 15:10:38 CET | Press release
Dentalis Animal Health appoints Advisory Board
AUTEL4.2.2023 09:01:43 CET | Press release
Autel Brings MaxiCharger DC Compact to eCarExpo and Signs Partnership Agreement with Leading Charging Operator Eways
MA-TAKEDA-PHARMACEUTICAL4.2.2023 00:49:44 CET | Press release
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
TX-SLB3.2.2023 22:06:49 CET | Press release
SLB Completes Acquisition of Gyrodata Incorporated
BDA3.2.2023 16:18:39 CET | Press release
Gallagher Re Joins ABIR and EY as 2023 Bermuda Risk Summit Headline Sponsors
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom